These findings led to the hypothesis that AD was associated with dysfunction in cholinergic signaling and the subsequent proposal of AChE inhibitors as potential candidates to treat AD, under the principle that increasing the concentrations of ACh would aid the cognitive symptoms and pathological progression of AD [23]. This evidence concerns the gene ACHE and Alzheimer disease.